Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 112 clinical trials
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm

lung carcinoma
atezolizumab
chemoradiotherapy
carboplatin
non-squamous non-small cell lung cancer
  • 86 views
  • 03 Jun, 2022
  • 34 locations
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to

immunodeficiency
cardiac disease
monoclonal antibodies
oophorectomy
insulin
  • 322 views
  • 28 Jun, 2022
  • 771 locations
  • 1 views
  • 24 Jun, 2022
  • 25 locations
  • 7 views
  • 28 Jun, 2022
  • 23 locations
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC

This is a randomized, multicenter, double-blind placebo-controlled phase 3 study of efficacy and safety of BCD-100 in combination with pemetrexed+cisplatin/carboplatin compared to placebo in

  • 2 views
  • 25 Jan, 2021
  • 36 locations
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

The anti-tumor activity of anti-PD-1 therapy and VEGF inhibitor in TKI-resistant EGFR-mutated Chinese non-squamous NSCLC patients will be investigated in this clinical trial.

vegf inhibitor
measurable disease
EGFR
metastasis
pemetrexed
  • 3 views
  • 21 Mar, 2022
  • 1 location
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

-788 group or Platinum-based chemotherapy group. Participants will receive TAK-788 orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening

  • 30 views
  • 11 May, 2022
  • 150 locations
ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (ABC-lung)

(Arm A) or atezolizumab, bevacizumab and pemetrexed (Arm B) in patients with stage IIIB-IV non-squamous non-small cell lung cancer (NSCLC) harbouring EGFR mutations after failure of standard EGFR

Accepts healthy volunteers
  • 42 views
  • 24 Mar, 2022
  • 17 locations
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS)

combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).

cancer chemotherapy
afatinib
tyrosine
gefitinib
kinase inhibitor
  • 14 views
  • 29 Jun, 2022
  • 92 locations
Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

when administered with pembrolizumab, pemetrexed and carboplatin in adults with nonsquamous non-small cell lung cancer (NSCLC) and MK-5890 when administered with pembrolizumab and nab-paclitaxel in

lung carcinoma
cancer chemotherapy
carboplatin
cancer
antineoplastic
  • 344 views
  • 19 Jun, 2022
  • 18 locations